Stocks Abbott Laboratories

More

  • The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.

  • A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.

  • FED_RESERVE3.jpg

    Oil prices will be the trigger for stocks in the week ahead. The Fed meets Tuesday and as usual, traders will watch for nuances in the Fed's post-meeting statement.

  • Heart Stent

    Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.

  • webxtra_thumb.jpg

    In Wednesday’s Web Extra Pete Najarian reveals why he thinks the solar trade is starting to turn. Also “if you want to get into drugs” Guy Adami has your play.

  • abbott_labs_earnngs.jpg

    Abbott Laboratories Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales of its medical devices, Humira arthritis treatment and other drugs.

  • Which is the Street more worried about--declining stock prices, particularly for financials, or inflation? It's both, and this morning's action illustrates that concern. It's been a roller coaster of a morning, up on Wells Fargo, down on consumer inflation higher than expected.

  • Oil's move could be a key trend in Wednesday's markets, as traders watch more Fed testimony, a bunch of earnings reports and another helping of inflation data.

  • To give investors an edge in this volatile market environment, CNBC asked the experts for their best trades now. 

  • At a time of market uncertainty, what can an investor count on?  Knee replacements, for one thing.  Bruce Nudell, UBS senior research analyst, takes that as his cue in picking some promising stocks.

  • The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.

  • graphic_word_ofthe_street.jpg

    The Dow rose Tuesday in another turbulent session after a pullback in oil prices eased worries about consumer and business spending. What's the "Word on the Street?"

  • Some traders are also turning bullish. John Mendelson of the Stanford Group issued a buy signal late in the day; traders tell me it was his 3rd buy signal in 5 years, and the prior two calls were very good.

  • Abbott Laboratories won U.S. approval to sell its drug-coated heart stent called Xience, the company said on Wednesday.

  • Heart Stent

    So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.

  • picks_pans_badge.jpg

    By anyone's reckoning, it was a rough week.  Crude oil continued its relentless climb; banks and brokerages gave hints of more discouraging news; government data pointed to a weak economy; even strong companies like Nike, Oracle, and Research In Motion issued cautious guidance; and Federal Reserve policymakers, widely perceived as powerless to help, left interest rates unchanged.  But all week, even through the worst of the market's sell-offs, CNBC guests offered

  • Where some stock-market investors see losses, Eric Schoenstein sees discounts.  His four-star Jensen Portfolio is up an average of 4.7 percent per year over the last three years, and he's singled out some stocks he finds exceptionally promising and very reasonably priced.

  • Fourth of July fireworks

    FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."

  • Following are the week’s biggest winners and losers. Find out why shares of Abbott Labs and Starbucks popped while CBS and Dillard's dropped.

  • Johnson & Johnson

    Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial for a heart stent is aimed at "millions of people who are ill-equipped to make judgments" about the device.